Inflammatory and endothelial dysfunction markers in females with metabolic syndrome aged 50–75 years

Introduction: The prevalence of metabolic syndrome (MetS) in Indonesia is 39% and it is higher in females than in males (46% vs. 28%). Features of this syndrome comprise low-grade chronic inflammation and endothelial dysfunction from cardiometabolic abnormalities. High-sensitive C-reactive protein (HsCRP) is a biomarker of cardiovascular disease, whereas ferritin and pentraxin-3 (PTX-3) are markers of chronic inflammation. One of the markers of endothelial dysfunction is an intercellular cell adhesion molecule-1 (ICAM-1). Studies on MetS in women aged 50–70 years and using several markers of inflammation and endothelial dysfunction are rare. The study aimed to determine differences in HsCRP, ferritin, PTX-3, and ICAM-1 level between females with and without MetS aged 50–75 years. Methods: For this cross-sectional study, 160 females aged 50–75 years from South Jakarta were recruited, divided into MetS and non-MetS (control) groups, 80 participants each. Participants that met the inclusion criteria were assessed for vital signs and metabolic parameters (e.g., lipid profile, fasting blood glucose level, and waist circumference [WC]). The groups were compared using an independent t-test for inflammatory (i.e., HsCRP, PTX-3, and ferritin) and endothelial dysfunction (ICAM-1) (p < 0.05) biomarkers. Results: The mean age of the MetS and control groups was 59.6 ± 5.6 and 59.2 ± 5.5 years. MetS criteria included WC of ≥80 cm (95.2%), increased blood pressure level (90.6%); and high-density lipoprotein cholesterol of <50 mg/dL (76.2%). Significant differences were found between the MetS and control groups for ferritin (p = 0.027), PTX-3 (p = 0.045), and ICAM-1 (p = 0.004) but not for HsCRP (p = 0.136). Conclusion: Elevated ferritin, PTX-3 level, and ICAM-1 level are significantly associated with an increased Mets risk in females aged 50–75 years; however, the same is not true for HsCRP.

[1]  A. Kuryłowicz Estrogens in Adipose Tissue Physiology and Obesity-Related Dysfunction , 2023, Biomedicines.

[2]  Jie Liu,et al.  Burden of Metabolic Syndrome Among a Low-Income Population in China: A Population-Based Cross-Sectional Study , 2022, Diabetes, metabolic syndrome and obesity : targets and therapy.

[3]  D. M. Tran,et al.  A Cross-Sectional Study of Serum Ferritin Levels in Vietnamese Adults with Metabolic Syndrome , 2022, Diabetes, metabolic syndrome and obesity : targets and therapy.

[4]  Safeera Khan,et al.  The Effect of Statin Therapy on Inflammatory Biomarkers: A Systematic Review , 2021, Cureus.

[5]  F. Azizi,et al.  Dietary and lifestyle inflammatory scores are associated with increased risk of metabolic syndrome in Iranian adults , 2021, Diabetology & Metabolic Syndrome.

[6]  N. Agarwal,et al.  Association of Serum Ferritin Levels with Metabolic Syndrome in India: a Cross-Sectional Study. , 2021, Maedica.

[7]  B. Elmas,et al.  Pentraxin 3 as a Marker for Cardiovascular Disease Risk in Overweight and Obese Children. , 2021, Acta Cardiologica Sinica.

[8]  G. Yuan,et al.  Combined Associations of Serum Ferritin and Body Size Phenotypes With Cardiovascular Risk Profiles: A Chinese Population-Based Study , 2021, Frontiers in Public Health.

[9]  C. Rubira,et al.  Association of Metabolic Syndrome and Hyperferritinemia in Patients at Cardiovascular Risk , 2020, Diabetes, metabolic syndrome and obesity : targets and therapy.

[10]  H. Falhammar,et al.  Genetic and Biological Effects of ICAM-1 E469K Polymorphism in Diabetic Kidney Disease , 2020, Journal of diabetes research.

[11]  H. Lee,et al.  The association between metabolic components and markers of inflammatory and endothelial dysfunction in adolescents, based on the Ewha Birth and Growth Cohort Study , 2020, PloS one.

[12]  Juan Antonio López-Rivera,et al.  The Impact of Education and Age on Metabolic Disorders , 2020, Frontiers in Public Health.

[13]  X. Shao,et al.  High-Sensitivity C-Reactive Protein Leads to Increased Incident Metabolic Syndrome in Women but Not in Men: A Five-Year Follow-Up Study in a Chinese Population , 2020, Diabetes, metabolic syndrome and obesity : targets and therapy.

[14]  Sujata Sharma,et al.  A Prospective Study on the Incidence of Metabolic Syndrome in Premenopausal and Postmenopausal Women , 2020, Journal of mid-life health.

[15]  P. Kris-Etherton,et al.  Aging women and their endothelium: Probing the relative role of estrogen on vasodilator function. , 2019, American journal of physiology. Heart and circulatory physiology.

[16]  M. Shin,et al.  Association of Plasma Pentraxin-3 Level with Lipid Levels and Cardiovascular Risk Factors in People with No History of Lipid-Lowering Medication: the Dong-gu Study , 2019, Journal of atherosclerosis and thrombosis.

[17]  D. R. Rios,et al.  Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation , 2019, International journal of molecular sciences.

[18]  A. Gabrielsen,et al.  hsCRP Level and the Risk of Death or Recurrent Cardiovascular Events in Patients With Myocardial Infarction: a Healthcare‐Based Study , 2019, Journal of the American Heart Association.

[19]  Y. Takashi,et al.  Circulating pentraxin 3 is positively associated with chronic hyperglycemia but negatively associated with plasma aldosterone concentration , 2018, PloS one.

[20]  R. Jayawardena,et al.  Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: a systematic review , 2017, BMC Public Health.

[21]  P. Altieri,et al.  The Metabolic Syndrome in Hispanics – The Role of Inflammation , 2015 .

[22]  Feng Liu,et al.  Pentraxin 3 as a Prognostic Biomarker in Patients with Systemic Inflammation or Infection , 2014, Mediators of inflammation.

[23]  S. Motor,et al.  Serum Pentraxin-3 Levels Are Associated with the Severity of Metabolic Syndrome , 2012, Medical Principles and Practice.

[24]  T. Kodama,et al.  Reciprocal Contribution of Pentraxin 3 and C‐Reactive Protein to Obesity and Metabolic Syndrome , 2010, Obesity.

[25]  A. Karaman,et al.  Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia. , 2009, Metabolic syndrome and related disorders.

[26]  G. Biolo,et al.  Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile , 2009, Clinical and Experimental Medicine.

[27]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[28]  L. Almasy,et al.  Intercellular adhesion molecule-1 concentration is genetically correlated with insulin resistance, obesity, and HDL concentration in Mexican Americans. , 2004, Diabetes.

[29]  A. Ayaz,et al.  Adipokines, inflammation, oxidative stress: critical components in obese women with metabolic syndrome , 2021 .

[30]  S. Kurtoğlu,et al.  Plasma Pentraxin 3 as a Biomarker of Metabolic Syndrome , 2014, The Indian Journal of Pediatrics.

[31]  M. Uzunlulu,et al.  Pentraxin 3 Levels as a Marker of Chronic Inflammation in Patients With Metabolic Syndrome , 2012 .

[32]  T. Kodama,et al.  Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations , 2009, Clinical chemistry and laboratory medicine.

[33]  A. Sañudo,et al.  Effects of Simvastatin and Metformin on Inflammation and Insulin Resistance in Individuals with Mild Metabolic Syndrome , 2007, American journal of cardiovascular drugs : drugs, devices, and other interventions.